{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:20:04Z","timestamp":1791404404005,"version":"4.3.3"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104913","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:57:22Z","timestamp":1755809842000},"page":"104913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Next-generation immunotherapy in relapsed\/refractory multiple myeloma: Strategies to achieve sustained MRD negativity"],"prefix":"10.1016","volume":"214","author":[{"given":"Ling","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-9363","authenticated-orcid":false,"given":"Muhammad Asad","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piaoqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.critrevonc.2025.104913_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115674","article-title":"Immunotherapy of multiple myeloma: current status as prologue to the future","volume":"24","author":"Abramson","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib2","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-Cell engagers and chimeric antigen receptor T-Cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib3","first-page":"17","article-title":"Chimeric antigen receptor t cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor t cells forward to earlier lines of therapy? Expert panel opinion from the American society for transplantation and cellular therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib4","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3390\/md13042327","article-title":"Fucoidan and cancer: a multifunctional molecule with anti-tumor potential","volume":"13","author":"Atashrazm","year":"2015","journal-title":"Mar. Drugs"},{"issue":"10214","key":"10.1016\/j.critrevonc.2025.104913_bib5","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104913_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1070353","article-title":"Innovation in BCMA CAR-T therapy: building beyond the model t","volume":"12","author":"Banerjee","year":"2022","journal-title":"Front. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104913_bib7","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) t cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104913_bib9","doi-asserted-by":"crossref","first-page":"15879","DOI":"10.3390\/ijms232415879","article-title":"Normalization of the immunological microenvironment and sustained minimal residual disease negativity: do we need both for Long-Term control of multiple myeloma?","volume":"23","author":"Bertuglia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104913_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415879","article-title":"Normalization of the immunological microenvironment and sustained minimal residual disease negativity: do we need both for Long-Term control of multiple myeloma?","volume":"23","author":"Bertuglia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib11","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/Refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104913_bib12","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib13","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2767-9764.CRC-21-0150","article-title":"Conduit CAR: redirecting CAR T-Cell specificity with a universal and adaptable bispecific antibody platform","volume":"2","author":"Borrok","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104913_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133213","article-title":"Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities","volume":"13","author":"Botta","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib15","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR t cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104913_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib19","article-title":"Acute kidney failure: when multiple myeloma Doesn\u00b4t give additional clues","volume":"12","author":"Cerqueira","year":"2020","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.25764","article-title":"Treatment and disease-related complications in multiple myeloma: implications for survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib21","article-title":"Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications","volume":"11","author":"Charalampous","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104913_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front. Immunol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104913_bib26","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2021-150124","article-title":"Sustainable efficacy and safety results from lummicar study 1: a phase 1\/2 study of fully human B-Cell maturation Antigen-Specific CAR t cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"\u03b3-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104913_bib28","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1182\/blood-2022-168610","article-title":"Phase \u2161 study of fully human BCMA-Targeting CAR-T cells (Zevorcabtagene Autoleucel) in patients with Relapsed\/Refractory multiple myeloma","volume":"140","author":"Chen","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.104913_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: a journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4062\/biomolther.2022.015","article-title":"Bispecific antibody-bound t cells as a novel anticancer immunotherapy","volume":"30","author":"Cho","year":"2022","journal-title":"Biomol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib33","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4049\/jimmunol.0804159","article-title":"Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy","volume":"184","author":"Condomines","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.999939","article-title":"The role of the bone microenvironment in regulating myeloma residual disease and treatment","volume":"12","author":"Dadzie","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: challenges encountered and future options for better treatment","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104913_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076300","article-title":"CAR t cell therapy: a versatile living drug","volume":"24","author":"De Marco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11092513","article-title":"The leading role of the immune microenvironment in multiple myeloma: a new target with a great prognostic and clinical value","volume":"11","author":"Desantis","year":"2022","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104913_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174082","article-title":"Multiple myeloma therapy: emerging trends and challenges","volume":"14","author":"Dima","year":"2022","journal-title":"Cancers"},{"issue":"10245","key":"10.1016\/j.critrevonc.2025.104913_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib42","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/s41375-020-01021-3","article-title":"Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib43","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for Relapsed\/Refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104913_bib44","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity","volume":"168","author":"Dredge","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib48","doi-asserted-by":"crossref","first-page":"9710","DOI":"10.3390\/curroncol30110705","article-title":"Multiple myeloma in 2023 ways: from trials to real life","volume":"30","author":"Fazio","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932852","article-title":"Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy","volume":"12","author":"Ferla","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib50","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a Meta-analysis","volume":"23","author":"Ficek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104913_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing t cell landscape determines the response to bispecific t cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104913_bib53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of t regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4252\/wjsc.v15.i5.421","article-title":"Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression","volume":"15","author":"Garc\u00eda-S\u00e1nchez","year":"2023","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.critrevonc.2025.104913_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CEOR.S367458","article-title":"The burden of a multiple myeloma diagnosis on patients and caregivers in the first year: Western european findings","volume":"14","author":"Gatopoulou","year":"2022","journal-title":"Clin. Outcomes Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104913_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174320","article-title":"Choosing the right therapy for patients with Relapsed\/Refractory multiple myeloma (RRMM) in consideration of Patient-, Disease- and Treatment-Related factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040669","article-title":"Drug combination in cancer treatment-from cocktails to conjugated combinations","volume":"13","author":"Gilad","year":"2021","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104913_bib58","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib59","first-page":"171","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib60","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","article-title":"Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: a young international society of geriatric oncology review paper","volume":"12","author":"Grant","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of t cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor t cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib64","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241231892","article-title":"The progress and prospects of immune cell therapy for the treatment of cancer","volume":"33","author":"Han","year":"2024","journal-title":"Cell Transpl."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104913_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153796","article-title":"A journey through the inter-cellular interactions in the bone marrow in multiple myeloma: implications for the next generation of treatments","volume":"14","author":"Herv\u00e1s-Salcedo","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020216","article-title":"Signaling pathway mediating myeloma cell growth and survival","volume":"13","author":"Hideshima","year":"2021","journal-title":"Cancers"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104913_bib68","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2023-178882","article-title":"The phase 2 CARTITUDE-2 trial: updated efficacy and safety of ciltacabtagene autoleucel in patients with multiple myeloma and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (Cohort B)","volume":"142","author":"Hillengass","year":"2023","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104913_bib69","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-Cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.leukres.2017.05.019","article-title":"Living with the burden of relapse in multiple myeloma from the patient and physician perspective","volume":"59","author":"Hulin","year":"2017","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.20517\/cdr.2022.23","article-title":"Therapeutics to harness the immune microenvironment in multiple myeloma","volume":"5","author":"Ignatz-Hoover","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-020-01124-6","article-title":"Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Med. Res. Methodol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib74","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.3109\/10428194.2014.1003057","article-title":"Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant","volume":"56","author":"Jimenez-Zepeda","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.mehy.2006.05.062","article-title":"Immunoglobulin is a highly diverse self-molecule that improves cellular diversity and function during immune reconstitution","volume":"68","author":"Jo\u00e3o","year":"2007","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.critrevonc.2025.104913_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1756-8722-6-13","article-title":"Validation of the M. D. anderson symptom inventory multiple myeloma module","volume":"6","author":"Jones","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib77","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.3324\/haematol.2015.134049","article-title":"Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study","volume":"101","author":"Jonsdottir","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ph14111172","article-title":"T cell bispecific antibodies: an Antibody-Based delivery system for inducing antitumor immunity","volume":"14","author":"Kamakura","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib79","first-page":"390.e1","article-title":"Patient-Reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor t cell therapy: a systematic review","volume":"27","author":"Kamal","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104913_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/antib12020038","article-title":"The role of bispecific antibodies in relapsed refractory multiple myeloma: a systematic review","volume":"12","author":"Khanam","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.critrevonc.2025.104913_bib83","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib84","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib85","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104913_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174290","article-title":"Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL)","volume":"14","author":"K\u00fcnz","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104913_bib87","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104913_bib88","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104913_bib89","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib90","first-page":"1243","article-title":"Current management and emerging treatment strategies for multiple myeloma","volume":"60","author":"Lei","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.critrevonc.2025.104913_bib91","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","author":"Lesokhin","year":"2024","journal-title":"Res Sq."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104913_bib92","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1182\/blood-2022-166465","article-title":"Updated results of Fumanba-1: a phase 1b\/2 study of a novel fully human B-Cell maturation Antigen-Specific CAR t cells (CT103A) in patients with relapsed and\/or refractory multiple myeloma","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104913_bib93","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","article-title":"CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed\/refractory multiple myeloma: updated results of phase 1b\/2 study (FUMANBA-1)","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104913_bib94","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2023-173427","article-title":"Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104913_bib96","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib97","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104913_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib99","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib100","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1401894","article-title":"Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ t cells","volume":"194","author":"Lu","year":"2015","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib101","doi-asserted-by":"crossref","DOI":"10.2196\/39068","article-title":"Characterizing the patient journey in multiple myeloma: qualitative review","volume":"8","author":"Lyall","year":"2022","journal-title":"JMIR Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib102","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.104913_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2025.104913_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032403","article-title":"The affinity of antigen-binding domain on the antitumor efficacy of CAR t cells: moderate is better","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104913_bib105","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib106","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","article-title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"39","author":"Martin","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib109","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI129205","article-title":"Immunotherapy of multiple myeloma","volume":"130","author":"Minnie","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.critrevonc.2025.104913_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.651288","article-title":"Autologous stem cell transplantation for myeloma: cytoreduction or an immunotherapy?","volume":"12","author":"Minnie","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11111721","article-title":"CAR-T-Cell therapy in multiple myeloma: B-Cell maturation antigen (BCMA) and beyond","volume":"11","author":"Mishra","year":"2023","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib112","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed\/refractory multiple myeloma","volume":"40","author":"Mol","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.critrevonc.2025.104913_bib113","first-page":"1","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","author":"Mol","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104913_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174206","article-title":"Single-Chain fragment variable: recent progress in cancer diagnosis and therapy","volume":"14","author":"Mu\u00f1oz-L\u00f3pez","year":"2022","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104913_bib115","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib117","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104913_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147627","article-title":"Targeting the microenvironment for treating multiple myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib119","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-022-00653-1","article-title":"Daratumumab plus lenalidomide\/bortezomib\/dexamethasone in black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN","volume":"12","author":"Nooka","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104913_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib121","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jha2.729","article-title":"T-cell redirecting bispecific antibodies in multiple myeloma: current landscape and future directions","volume":"4","author":"O'Neill","year":"2023","journal-title":"EJHaem"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061243","article-title":"Bispecific antibodies in cancer immunotherapy: a novel response to an old question","volume":"14","author":"Ord\u00f3\u00f1ez-Reyes","year":"2022","journal-title":"Pharmaceutics"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104913_bib123","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib124","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib126","first-page":"275","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104913_bib127","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","author":"Perrot","year":"2025","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med. Decis. Mak."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of national institute for health and care excellence technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104913_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/Refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104913_bib131","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor t cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib132","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results","volume":"4","author":"Raab","year":"2023","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib133","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib134","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib135","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2025.104913_bib136","first-page":"119","article-title":"CAR T-Cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib137","first-page":"220","article-title":"Autologous stem cell transplantation in multiple myeloma","volume":"62","author":"Ricciuti","year":"2020","journal-title":"Panminerva Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104913_bib138","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/10428194.2021.1913143","article-title":"Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor\u2009+\u2009dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma","volume":"62","author":"Rodriguez-Otero","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib139","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104913_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib141","article-title":"The role of chimeric antigen Receptor-T cell therapy in the treatment of hematological malignancies: advantages, trials, and tribulations, and the road ahead","volume":"13","author":"Rohit Reddy","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11010059","article-title":"Advancements in cancer immunotherapies","volume":"11","author":"Roy","year":"2022","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104913_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11091534","article-title":"Clonal evolution of multiple Myeloma-Clinical and diagnostic implications","volume":"11","author":"Salomon-Perzy\u0144ski","year":"2021","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib144","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib146","article-title":"Oncological horizons: the synergy of medical and surgical innovations in cancer treatment","volume":"15","author":"Shams","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2025.104913_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR t therapies in multiple myeloma: unleashing the future","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104913_bib148","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/biomedicines11072087","article-title":"Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting","volume":"11","author":"Solimando","year":"2023","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib149","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, Open-Label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104913_bib150","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/1078-0432.CCR-21-0168","article-title":"Antidrug antibodies and drug development: challenges in the immunotherapy era","volume":"27","author":"de Sp\u00e9ville","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib151","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric antigen receptor t cell therapy: challenges to Bench-to-Bedside efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104913_bib152","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104913_bib153","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.3390\/cancers13194867","article-title":"Treatment strategy for multiple myeloma to improve immunological environment and maintain MRD negativity","volume":"13","author":"Suzuki","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib154","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104913_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061819","article-title":"Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety","volume":"15","author":"Swan","year":"2023","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104913_bib156","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"April and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104913_bib157","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib158","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1358\/dot.2022.58.3.3381592","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: a review of recent advances","volume":"58","author":"Tu","year":"2022","journal-title":"Drugs Today (Barc)"},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104913_bib159","article-title":"KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma","volume":"39","author":"Usmani","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104913_bib160","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex Vivo-Expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104913_bib161","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104913_bib162","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib163","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12672-024-00891-8","article-title":"Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104913_bib164","first-page":"431","article-title":"Assessment tools for patient-reported outcomes in multiple myeloma","volume":"31","author":"Wang","year":"2023","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104913_bib165","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.783703","article-title":"Early dynamics and depth of response in multiple myeloma patients treated with BCMA CAR-T cells","volume":"11","author":"Wong","year":"2021","journal-title":"Front. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104913_bib168","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib169","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40164-021-00250-1","article-title":"Recent advances and challenges of bispecific antibodies in solid tumors","volume":"10","author":"Wu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104913_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082240","article-title":"Targeting BCMA in multiple myeloma: advances in Antibody-Drug conjugate therapy","volume":"15","author":"Xing","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104913_bib171","article-title":"Harnessing the immune system against multiple myeloma: challenges and opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib172","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib173","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104913_bib174","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor t cell therapy directed against b cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104913_bib176","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/BS9.0000000000000025","article-title":"Current status and hurdles for CAR-T cell immune therapy","volume":"1","author":"Zhao","year":"2019","journal-title":"Blood Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104913_bib177","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104913_bib178","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J. Immunother. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:30:24Z","timestamp":1762353024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":178,"alternative-id":["S1040842825003014"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104913","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation immunotherapy in relapsed\/refractory multiple myeloma: Strategies to achieve sustained MRD negativity","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104913"}}